The trajectory of companies tied to Viagra's legacy presents a intricate investment scenario . While the initial success generated substantial profits , generic copies have significantly eroded revenue. Investing in connected pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving healthcare trends , and the